In a competitive pharma marked by surging imports, shifting market dynamics, tighter regulations, and sweeping administrative reforms, Davipharm – a member of Adamed Group, one of Vietnam’s leading domestic drug manufacturers has emerged as a notable player.

According to IQVIA data for Q3/2025, Davipharm ranks Top 7 among local companies in ethical drug sales, outperforming a contracting domestic market with continued growth, particularly in the retail channel. The company’s 2026 strategy reflects a long-term commitment to strengthening Vietnam’s domestic pharmaceutical capacity while positioning the company as a global supplier.

Innovation, manufacturing investment & export ambitions

In 2026, Davipharm plans to launch 20 new products, reinforcing its focus on high-quality generics and addressing unmet medical needs. Research and development remains central to the company’s roadmap, with nearly USD 20 million committed to R&D investment between 2026 and 2030.

On February 4th 2026, Davipharm marked a major milestone with the opening of its High-Potency R&D Formulation Laboratory at its Ho Chi Minh City factory. Designed for early-phase formulation and optimization of highly active products, the facility underscores the company’s expanding R&D capabilities, with a strong emphasis on employee safety, quality assurance, and controlled development environments.

Photo: Davipharm’s new high-potency R&D formulation laboratory has just been inaugurated in February 2026

Manufacturing capacity expansion is also high on the agenda. Davipharm is preparing its plants for ANVISA standards, while total CAPEX investment for factories, warehouses, production lines, and laboratories from 2026 to 2030 is expected to exceed USD 25 million. Continuous Kaizen programs are being implemented to improve productivity, quality consistency, and operational excellence.

Davipharm aims to strengthen Vietnam’s domestic pharmaceutical production, reduce reliance on imports, and boost the export of high-quality generic drugs. The company is positioning itself as a Southeast Asian export hub, with products registered across ASEAN markets and expanded global licensing-out activities.

The investment aligns with Adamed’s broader strategy of strengthening Vietnam as a key production hub in Asia, enhancing supply chain resilience and manufacturing sustainability.

Quality, compliance and international growth

Quality remains a cornerstone of Davipharm. The company has outlined a roadmap to elevate quality standards through technology upgrades, workforce training, and global benchmarking, ensuring alignment with international GMP expectations.

Photo: Inside the first EU-GMP certified HP Zone in Vietnam and the region at Davipharm.

International expansion is a key pillar of Davipharm’s growth strategy. By 2033, the company aspires to become Vietnam’s leading domestic pharmaceutical exporter. Its focus is on manufacturing EU-GMP, Philippines FDA, EAEU-GMP, ANVISA compliant products to expand beyond Southeast Asia into Europe, South America, and other global markets.

Digital transformation is also being applied across operations from production to customer engagement enhancing efficiency and transparency across the supply chain.

People, community and sustainability aspirations

Davipharm consistently emphasizes that people are at the heart of its growth. People development is a strategic pillar, with strong investments in training program such as Compliance, Certified Investigators & Auditors, Future Leaders, First-Time Manager, and the launch of a new e-learning platform. The company has been also active with Adamed’s global mobility initiatives, multicultural engagement like Adamed Values Day, and close collaboration with universities through internships and career talks.

Beyond business, Davipharm has built a strong track record in social responsibility. From 2021 until now, it is the first and only domestic pharmaceutical company to partner with Ministry of Health in implementing the national program for prevention and early detection of non-communicable diseases (NCDs). Through “Vietnam Healthcare” initiative, nearly 30,000 people have received screening and consultations for hypertension, diabetes, gout, dyslipidemia, osteoporosis, and mental health disorders. The program has reached around 10 million people through health education and supported the training of nearly 3,000 doctors nationwide.

Photo: Vietnam Healthcare program’s free NCDs screening for the community at Le Van Thinh hospital (HCMC)

In education, the ADAMED SmartUP program has supported more than 950 students at Vietnam – Poland High School since 2019, including science camps in Poland for outstanding students. The program will continue in 2026 with international mentoring exposure, and the selection of top-performing students for a summer camp in Poland.

Ultimately, Davipharm’s aspirations remain clear: ensuring wide availability of high quality and affordable drugs for patients nationwide, becoming the top-of-mind choice for Vietnamese doctors, pharmacists, and patients, and reinforcing its role as a socially responsible pharmaceutical company that cares for people and education starting from local communities.

As Vietnam’s healthcare system evolves, Davipharm’s 2026 strategy signals a confident step forward anchored in quality, innovation, and a clear vision to elevate the image of made in Vietnam medicines, supply products to local and international markets.

Source: VTV.vn